Iovance Biotherapeutics, Inc. IOVA Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s operating lease right-of-use asset amortization?
- Iovance Biotherapeutics, Inc. (IOVA) reported operating lease right-of-use asset amortization of $1.88M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Iovance Biotherapeutics, Inc.'s operating lease right-of-use asset amortization decreased by 34.6% year-over-year, from $2.87M to $1.88M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s operating lease right-of-use asset amortization has grown at a 1.2% compound annual growth rate (CAGR), from $10.87M to $11.39M.